Currently, four small-molecule BTK inhibitors have been approved by the U.S. Food and Drug Administration (FDA) for treatment of mantle cell lymphoma, chronic lymphocytic leukemia and small lymphocytic lymphoma. Here, BTK is linked to B-cell chronic lymphocytic leukemia.